Cerebrospinal fluid tau and Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment

Neuroscience Letters

Volumn 273, Issue 1, 1999, Pages 5-8

  Andreasen, N ^a   Minthon, L ^b   Vanmechelen, E ^c   Vanderstichele, H ^c   Davidsson, P ^d   Winblad, B ^e   Blennow, K ^d,f  

^a Pitea River Valley Hospital   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c INNOGENETICS   (Belgium)

^d Department of Clinical Neuroscience   (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f MEDICAL RESEARCH COUNCIL   (Sweden)

Author keywords

amyloid; Alzheimer's disease; Biochemical markers; Cerebrospinal fluid; Sensitivity; Tau

Indexed keywords

AMYLOID BETA PROTEIN; BIOCHEMICAL MARKER; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE COURSE; HUMAN; PREDICTION; PRIORITY JOURNAL;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; COGNITION DISORDERS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; TAU PROTEINS;

EID: 0032857103     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(99)00617-5     Document Type: Article

References (20)

1. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 4th edn., American Psychiatric Association, Washington DC, 1994, p. 142.
2. Andreasen N., Vanmechelen E., Van de Voorde E., Davidsson P., Hesse C., Tarvonen S., Räihä I., Sourander L., Winblad B., Blennow K. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. J. Neurol. Neurosurg. Psychiatry. 64:1998;298-305.
3. Andreasen N., Sjö̈din C., Blennow K., Winblad B., Svärsudd K. Prevalence and incidence of memory recall disturbances in a geographically defined general population. The Piteȧ Dementia Project. Neuroepidemiology. 18:1999;144-155.
4. (1-42) in Alzheimer's disease: differences between early- and late-onset AD and stability during the course of disease. Arch. Neurol. 56:1999;673-680.
5. Blennow K., Wallin A., Agren H., Spenger C., Siegfried J., Vanmechlen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer's disease? Mol. Chem. Neuropathol. 26:1995;231-245.
6. Davies L., Wolska B., Hilbich C., Multhaup G., Martins R., Simms G., Beyreuther K., Masters C.L. A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques. Neurology. 38:1988;1688-1693.
7. Folstein M., Folstein S., McHugh P. 'Mini-Mental State' A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12:1975;189-198.
8. Galasko D., Clark C., Chang L., Miller B., Green R.C., Motter R., Seubert P. Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease. Neurology. 48:1997;632-635.
9. Galasko D., Clark C., Chang L., Miller B., Green R.C., Motter R., Seubert P. High cerebrospinal fluid tau and low amyloid beta 42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch. Neurol. 55:1998;937-945.
10. Hulstaert F., Blennow K., Ivanoiu A., Schoonderwaldt H.C., Riemenschneider M., De Deyn P.P., Bancher C., Cras P., Wiltfang J., Mehta P.D., Iqbal K., Pottel H., Vanmechelen E., Vanderstichele H. Improved discrimination of Alzheimer's disease patients from other subject groups using the combined measure of β-amyloid(1-42) and tau in CSF; a multicenter study. Neurology. 52:1999;1555-1562.
11. Iwatsubo T., Odaka A., Suzuki N., Mizusawa H., Nukina N., Ihara Y. Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific A(monocloncals: evidence that an initially deposited species is Aβ42(43). Neuron. 13:1994;45-53.
12. Jellinger K.A., Bancher C. Neuropathology of Alzheimer's disease: a critical update. J. Neural. Transm. 54:1998;77-95.
13. Kurz A., Riemenschneider M., Buch K., Willoch F., Bartenstein P., Muller U., Guder W. Tau protein in cerebrospinal fluid is significantly increased at the earliest clinical stage of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 12:1998;372-377.
14. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology. 34:1984;939-944.
15. Motter R., Vigo-Pelfrey C., Kholodenko D., Barbour R., Johnson-Wood K., Galasko D., Chang L., Miller B., Clark C., Green R., Olson D., Southwick P., Wolfert R., Munroe B., Lieberburg I., Seubert P., Schenk D. Reduction of β-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol. 38:1995;643-648.
16. Petersen R.C., Smith G.E., Ivnik R.J., Tangalos E.G., Schaid D.J., Thibodeau S.N., Kokmen E., Waring S.C., Kurland L.T. Apolipoprotein E, status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. J. Am. Med. Assoc. 273:1995;1274-1278.
17. Price J.L., Morris J.C. Tangles and plaques in nondemented aging and 'preclinical' Alzheimer's disease. Ann. Neurol. 45:1999;358-368.
18. Riemenschneider M., Buch K., Schmolke M., Kurz A., Guder W.G. Cerebrospinal protein tau is elevated in early Alzheimer's disease. Neurosci. Lett. 212:1996;209-211.
19. Tapiola T., Overmyer M., Lehtovirta M., Helisalmi S., Ramberg J., Alafuzoff I., Riekkiinen Sr.P., Soininen H. The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease. NeuroReport. 8:1997;3961-3963.
20. (1-42) in CSF. Fisher A., Hanin I., Yoshida M. Alzheimer's and Parkinson's Diseases. 1998;773-778 Plenum Press, New York.